Trial · NCT04287985
Outcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Adverse Events Graded by Severity | Baseline to End of Study (16 months) | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Changes From Baseline in Clinical Laboratory Tests | Baseline to End of Study (16 months) | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Clinically Meaningful Changes From Baseline in Vital Signs | Baseline to End of Study (16 months) | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Clinically Significant Physical Examinations | Baseline to End of Study (16 months) | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Change From Baseline in uPCR: Month 12 | 12 months | modified intent-to-treat (mITT) Population | g/g | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in uPCR: Months 9 and 16 | Baseline to 9 months and 16 months (16 months total) | modified intent-to-treat (mITT) Population | g/g | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 24-hour Urine Protein Excretion: Months 12 and 16 | 16 months | modified intent-to-treat (mITT) Population | mg/day | GEOMETRIC_MEAN |
| SECONDARY | Participants Achieving a Greater Than or Equal to 30% Decline From Baseline in uPCR at Months 9, 12, and 16 | Baseline to 9,12, and 16 months (16 months total) | modified intent-to-treat (mITT) Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Participants in Each Group Achieving Clinical Remission | Baseline to End of Study (16 months) | modified intent-to-treat (mITT) Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in eGFR at Months 9, 12, and 16 | Baseline to 12 and 16 months | modified intent-to-treat (mITT) Population | mL/min/1.73 m^2 | MEAN |
| SECONDARY | Percent Change From Baseline in Total Serum IgA, IgG, and IgM Concentrations at Months 12 and 16 | Baseline to 12 and 16 months | Pharmacodynamic Population | percentage change | MEAN |
| SECONDARY | Mean Serum PK Parameters at Month 0 and Month 11: Cmax | Months 0 and 11 | Intensive Pharmacokinetic Population | μg/mL | MEAN |
| SECONDARY | Median Serum PK Parameters at Month 0 and Month 11: Tmax | Month 0 and Month 11 | Intensive Pharmacokinetic Population | days | MEDIAN |
| SECONDARY | Mean Serum PK Parameters at Month 0: AUC0-inf and AUC0-30 | Month 0 | Intensive pharmacokinetic population | day∙μg/mL | MEAN |
| SECONDARY | Mean Serum PK Parameters at Month 0 and Month 11: t1/2z | Month 0 and Month 11 | Intensive Pharmacokinetic Population | days | MEAN |
| SECONDARY | Median Serum PK Parameters at Month 0: CL | Month 0 | Intensive pharmacokinetic population | mL/day | MEDIAN |
| SECONDARY | Mean Serum PK Parameters at Month 0: Vz | Month 0 | Intensive pharmacokinetic population | mL | MEAN |
| SECONDARY | Mean Serum PK Parameters at Month 11: AUCτ | Month 11 | Intensive Pharmacokinetic Population | day∙μg/mL | MEAN |
| SECONDARY | Mean Serum PK Parameters at Month 11: Vss | Month 11 | Intensive Pharmacokinetic Population | mL/kg | MEAN |
| SECONDARY | Mean Serum PK Parameters at Month 11: CLss | Month 11 | Intensive Pharmacokinetic Population | mL/day | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04287985/outcomes